Skip to search formSkip to main contentSkip to account menu

Zyrtec

Known as: Reactine, Pfizer Brand of Cetirizine Dihydrochloride, UCB Brand of Cetirizine Dihydrochloride 
brand name of an allergy medicine
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

Cetirizinecetirizine hydrochloride

Narrower (2)

cetirizine hydrochloride 1 MG/ML Oral Solutioncetirizine hydrochloride 10 MG Oral Tablet
cetirizine hydrochloride 5 MG Chewable Tablet [Zyrtec]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled…
Background Dual neutralisation of IL-17F, in addition to IL-17A, reduces inflammation1 to a greater extent than inhibition of IL… 
Review
2018
Review
2018
FRI0693 Fears and misconceptions of women with chronic rheumatic diseases on their journey to motherhood
Background: Recent EULAR ‘Points to Consider’ provide guidance on management and treatment of Women of Childbearing Age (WoCBA… 
Review
2017
Review
2017
OP0051 The activating patients at risk for osteoporosis study: a randomized trial within the global longitudinal study of osteoporosis in women cohort
Background Osteoporosis treatment rates are declining, even among those with past fractures. Novel, low cost approaches engaging… 
2017
2017
FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study
Background Women with active chronic rheumatic inflammatory conditions (RA, PsA, AxSpA) often face uncertainty regarding the… 
2016
2016
OP0108 Bimekizumab, A Monoclonal Antibody That Inhibits both IL-17A and IL-17F, Produces A Profound Response in both Skin and Joints: Results of An Early-Phase, Proof-of-Concept Study in Psoriatic…
Background Bimekizumab (UCB4940) is a potent and selective monoclonal antibody inhibiting the activity of both IL-17A and IL-17F… 
2013
2013
THU0192 5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis
Background In the RAPID 1 randomized clinical trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX… 
2013
2013
THU0512 Rheumatoid Arthritis (RA), Comorbidities and Biological Agents Uptake in France: Analysis of a National Claims Database
Background Claims databases are useful tools to conduct epidemiological studies on representative samples in terms of patient’s… 
Review
2012
Review
2012
Perampanel, a Selective, Non-Competitive AMPA Receptor Antagonist as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures: A Dose Response Analysis from Phase III Studies (P06.117)
Objective: Examine perampanel dose-response by pooled analysis of randomized, double-blind phase III studies (304/305/306) and… 
2010
2010
Reversal of Hepatic Fibrosis by Human CD34(+) Stem/Progenitor Cell Transplantation in Rats.
Human umbilical cord blood (UCB) cells have many advantages as grafts for cell transplantation. Here, we transplant UCB cells… 
1982
1982
Pharmacology of a new orally active antiallergic: pyrido[1,2-a]pyrimidine, ucb L140 (CHINOIN 1045) in rats.
ucb L140 (CHINOIN 1045) has been tested in various rat anaphylaxis systems. In models of passive cutaneous anaphylaxis (PCA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)